DOSTARLIMAB\DOSTARLIMAB-GXLY: 69 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
69
Total FAERS Reports
10 (14.5%)
Deaths Reported
25
Hospitalizations
69
As Primary/Secondary Suspect
5
Life-Threatening
First Report: 20230803 · Latest Report: 20241201
What Are the Most Common DOSTARLIMAB\DOSTARLIMAB-GXLY Side Effects?
#1 Most Reported
Rash
7 reports (10.1%)
#2 Most Reported
Myocarditis
7 reports (10.1%)
#3 Most Reported
Lichenoid keratosis
5 reports (7.2%)
All DOSTARLIMAB\DOSTARLIMAB-GXLY Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Myocarditis | 7 | 10.1% | 1 | 1 |
| Rash | 7 | 10.1% | 0 | 2 |
| Dermatitis bullous | 5 | 7.3% | 0 | 5 |
| Hepatitis | 5 | 7.3% | 0 | 5 |
| Lichenoid keratosis | 5 | 7.3% | 0 | 5 |
Who Reports DOSTARLIMAB\DOSTARLIMAB-GXLY Side Effects? Age & Gender Data
Gender: 100.0% female, 0.0% male. Average age: 73.0 years. Most reports from: FR. View detailed demographics →
Is DOSTARLIMAB\DOSTARLIMAB-GXLY Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2023 | 2 | 0 | 1 |
| 2024 | 32 | 5 | 17 |
What Is DOSTARLIMAB\DOSTARLIMAB-GXLY Used For?
| Indication | Reports |
|---|---|
| Endometrial cancer | 20 |
| Product used for unknown indication | 16 |
| Papillary serous endometrial carcinoma | 10 |
| Endometrial cancer metastatic | 7 |
| Endometrial adenocarcinoma | 6 |
Official FDA Label for DOSTARLIMAB\DOSTARLIMAB-GXLY
Official prescribing information from the FDA-approved drug label.